
Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.

Your AI-Trained Oncology Knowledge Connection!


Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.

Published: November 5th 2019 | Updated: